Enveric Biosciences (ENVB)
Market Price (6/17/2026): $1.38 | Market Cap: $2.1 MilSector: Health Care | Industry: Biotechnology
Enveric Biosciences (ENVB)
Market Price (6/17/2026): $1.38Market Cap: $2.1 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -237% Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -139%, 3Y Excs Rtn is -175% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.2 Mil Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -402% High stock price volatilityVol 12M is 175% Key risksENVB key risks include [1] its precarious financial health as a pre-revenue company with ongoing losses and [2] a critically high 86% probability of bankruptcy, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -237% |
| Megatrend and thematic driversMegatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Biopharmaceutical R&D, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -139%, 3Y Excs Rtn is -175% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.2 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -402% |
| High stock price volatilityVol 12M is 175% |
| Key risksENVB key risks include [1] its precarious financial health as a pre-revenue company with ongoing losses and [2] a critically high 86% probability of bankruptcy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 6/15/2026
Enveric Biosciences (ENVB) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Persistent "Going Concern" Uncertainty and Weak Financials.
Enveric Biosciences reported a net loss of $1.63 million for fiscal Q1 2026, which ended on March 31, 2026, alongside a negative operating cash flow of $2.26 million. Critically, the company raised "substantial doubt about its ability to continue as a going concern" over the next year, signaling significant financial risk to investors.
2. Significant Shareholder Dilution from Continuous Equity Offerings.
The company has relied heavily on equity financing to support its operations, leading to substantial dilution for existing shareholders. Enveric Biosciences raised $2.50 million in fiscal Q1 2026 and secured an additional $4.5 million in April 2026 through equity-linked financings. A private placement in April 2026 could generate up to $13.9 million from the sale of shares and warrants. This pattern has contributed to a reported 1687.6% increase in total shares outstanding over the past year, significantly impacting per-share value.
Show more
Enveric Biosciences (ENVB) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Persistent "Going Concern" Uncertainty and Weak Financials.
Enveric Biosciences reported a net loss of $1.63 million for fiscal Q1 2026, which ended on March 31, 2026, alongside a negative operating cash flow of $2.26 million. Critically, the company raised "substantial doubt about its ability to continue as a going concern" over the next year, signaling significant financial risk to investors.
2. Significant Shareholder Dilution from Continuous Equity Offerings.
The company has relied heavily on equity financing to support its operations, leading to substantial dilution for existing shareholders. Enveric Biosciences raised $2.50 million in fiscal Q1 2026 and secured an additional $4.5 million in April 2026 through equity-linked financings. A private placement in April 2026 could generate up to $13.9 million from the sale of shares and warrants. This pattern has contributed to a reported 1687.6% increase in total shares outstanding over the past year, significantly impacting per-share value.
Show more
Updated on 6/15/2026
Enveric Biosciences (ENVB) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Persistent "Going Concern" Uncertainty and Weak Financials.
Enveric Biosciences reported a net loss of $1.63 million for fiscal Q1 2026, which ended on March 31, 2026, alongside a negative operating cash flow of $2.26 million. Critically, the company raised "substantial doubt about its ability to continue as a going concern" over the next year, signaling significant financial risk to investors.
2. Significant Shareholder Dilution from Continuous Equity Offerings.
The company has relied heavily on equity financing to support its operations, leading to substantial dilution for existing shareholders. Enveric Biosciences raised $2.50 million in fiscal Q1 2026 and secured an additional $4.5 million in April 2026 through equity-linked financings. A private placement in April 2026 could generate up to $13.9 million from the sale of shares and warrants. This pattern has contributed to a reported 1687.6% increase in total shares outstanding over the past year, significantly impacting per-share value.
3. Inability to Sustain Positive Catalysts Amidst Financial Pressures.
Despite some positive news, such as favorable preclinical results for its lead drug candidate EB-003 and the issuance of a new U.S. patent for its EVM301 series in April 2026, which caused a temporary stock surge of over 150%, these gains were not sustained. The subsequent decline indicates that while specific positive developments can generate short-term interest, the underlying financial instability, including the "going concern" warning and ongoing need for capital, outweighed these catalysts, leading to the net loss in the specified period.
Show less
Enveric Biosciences (ENVB) stock has lost about 40% since 2/28/2026 because of the following key factors:
1. Persistent "Going Concern" Uncertainty and Weak Financials.
Enveric Biosciences reported a net loss of $1.63 million for fiscal Q1 2026, which ended on March 31, 2026, alongside a negative operating cash flow of $2.26 million. Critically, the company raised "substantial doubt about its ability to continue as a going concern" over the next year, signaling significant financial risk to investors.
2. Significant Shareholder Dilution from Continuous Equity Offerings.
The company has relied heavily on equity financing to support its operations, leading to substantial dilution for existing shareholders. Enveric Biosciences raised $2.50 million in fiscal Q1 2026 and secured an additional $4.5 million in April 2026 through equity-linked financings. A private placement in April 2026 could generate up to $13.9 million from the sale of shares and warrants. This pattern has contributed to a reported 1687.6% increase in total shares outstanding over the past year, significantly impacting per-share value.
3. Inability to Sustain Positive Catalysts Amidst Financial Pressures.
Despite some positive news, such as favorable preclinical results for its lead drug candidate EB-003 and the issuance of a new U.S. patent for its EVM301 series in April 2026, which caused a temporary stock surge of over 150%, these gains were not sustained. The subsequent decline indicates that while specific positive developments can generate short-term interest, the underlying financial instability, including the "going concern" warning and ongoing need for capital, outweighed these catalysts, leading to the net loss in the specified period.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -41.7% change in ENVB stock from 2/28/2026 to 6/16/2026 was primarily driven by a -79.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282026 | 6162026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.35 | 1.37 | -41.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -79.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
2/28/2026 to 6/16/2026| Return | Correlation | |
|---|---|---|
| ENVB | -41.7% | |
| Market (SPY) | 9.7% | 4.3% |
| Sector (XLV) | -4.1% | -17.6% |
Fundamental Drivers
The -76.1% change in ENVB stock from 11/30/2025 to 6/16/2026 was primarily driven by a -79.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 11302025 | 6162026 | Change |
|---|---|---|---|
| Stock Price ($) | 5.74 | 1.37 | -76.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -79.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
11/30/2025 to 6/16/2026| Return | Correlation | |
|---|---|---|
| ENVB | -76.1% | |
| Market (SPY) | 10.4% | 6.3% |
| Sector (XLV) | -2.2% | -4.9% |
Fundamental Drivers
The -90.3% change in ENVB stock from 5/31/2025 to 6/16/2026 was primarily driven by a -90.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312025 | 6162026 | Change |
|---|---|---|---|
| Stock Price ($) | 14.16 | 1.37 | -90.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -90.1% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2025 to 6/16/2026| Return | Correlation | |
|---|---|---|
| ENVB | -90.3% | |
| Market (SPY) | 28.8% | 11.2% |
| Sector (XLV) | 17.4% | -0.7% |
Fundamental Drivers
The -99.8% change in ENVB stock from 5/31/2023 to 6/16/2026 was primarily driven by a -99.2% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 5312023 | 6162026 | Change |
|---|---|---|---|
| Stock Price ($) | 754.20 | 1.37 | -99.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 0 | 2 | -99.2% |
| Cumulative Contribution | 0.0% |
Market Drivers
5/31/2023 to 6/16/2026| Return | Correlation | |
|---|---|---|
| ENVB | -99.8% | |
| Market (SPY) | 86.6% | 10.9% |
| Sector (XLV) | 25.8% | 3.7% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| ENVB Return | -78% | -96% | -38% | -72% | -94% | -59% | -100% |
| Peers Return | -56% | -31% | -21% | -35% | 294% | 29% | -20% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 10% | 101% |
Monthly Win Rates [3] | |||||||
| ENVB Win Rate | 25% | 17% | 33% | 33% | 33% | 17% | |
| Peers Win Rate | 39% | 50% | 44% | 40% | 65% | 54% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| ENVB Max Drawdown | -81% | -97% | -73% | -81% | -96% | -72% | |
| Peers Max Drawdown | -75% | -77% | -59% | -71% | -53% | -27% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ATAI, RLMD, AXSM, NRXP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 6/16/2026 (YTD)
How Low Can It Go
| Event | ENVB | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -50.0% | -6.7% |
| % Gain to Breakeven | 100.0% | 7.1% |
| Time to Breakeven | 37 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.5% | -33.7% |
| % Gain to Breakeven | 94.1% | 50.9% |
| Time to Breakeven | 47 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -57.1% | -0.2% |
| % Gain to Breakeven | 133.0% | 0.2% |
| Time to Breakeven | 137 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -90.5% | -17.9% |
| % Gain to Breakeven | 950.0% | 21.8% |
| Time to Breakeven | 30 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -71.7% | -53.4% |
| % Gain to Breakeven | 253.9% | 114.4% |
| Time to Breakeven | 9 days | 1085 days |
In The Past
Enveric Biosciences's stock fell -5.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 6.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | ENVB | S&P 500 |
|---|---|---|
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -50.0% | -6.7% |
| % Gain to Breakeven | 100.0% | 7.1% |
| Time to Breakeven | 37 days | 31 days |
| 2020 COVID-19 Crash | ||
| % Loss | -48.5% | -33.7% |
| % Gain to Breakeven | 94.1% | 50.9% |
| Time to Breakeven | 47 days | 140 days |
| 2013 Taper Tantrum | ||
| % Loss | -57.1% | -0.2% |
| % Gain to Breakeven | 133.0% | 0.2% |
| Time to Breakeven | 137 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -90.5% | -17.9% |
| % Gain to Breakeven | 950.0% | 21.8% |
| Time to Breakeven | 30 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -71.7% | -53.4% |
| % Gain to Breakeven | 253.9% | 114.4% |
| Time to Breakeven | 9 days | 1085 days |
In The Past
Enveric Biosciences's stock fell -5.6% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 6.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Enveric Biosciences (ENVB)
Enveric Biosciences (ENVB) is a pharmaceutical company dedicated to developing innovative cannabinoid-based medicines. The company's core focus is on addressing unmet medical needs within cancer care, leveraging cannabinoids to create new therapeutic options. Beyond oncology, Enveric is also expanding its research and development efforts into other significant health areas, including mental health indications and chronic pain conditions like osteoarthritis.
The company's pipeline features several distinct investigational products aimed at diverse patient populations. For cancer patients, Enveric is developing EVM-101 and EVM-201 to alleviate cancer-related distress, as well as EV101, which combines cannabinoids with traditional chemotherapy. Outside of cancer treatment, its offerings include EV104 for osteoarthritis, EVM-301 for mental health applications, and EV102, a cannabinoid cream designed for topical skin use. These products are being developed to serve patients seeking novel, cannabinoid-derived treatments across a broad spectrum of medical conditions.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Enveric Biosciences:
- Like GW Pharmaceuticals, but focusing on a broader range of cannabinoid-derived medicines for conditions like cancer care, pain, and mental health.
- Think of them like a biotech company such as Moderna or BioNTech, but instead of mRNA, they're developing new medicines from cannabinoids.
AI Analysis | Feedback
```html
- EV104: A product in development for the treatment of osteoarthritis.
- EVM-101 and EVM-201: Medicines under development for the treatment of cancer-related distress.
- EVM-301: A developmental therapy targeting mental health indications.
- EV102: A cannabinoid cream designed for topical skin application.
- EV101: A combination therapy involving cannabinoids and chemotherapy.
AI Analysis | Feedback
Enveric Biosciences (ENVB) is a pharmaceutical company primarily engaged in the research and development of various cannabinoid medicines. According to the company description, its pipeline consists of drug candidates for conditions such as osteoarthritis, cancer-related distress, mental health indications, and topical skin applications. These products are in development stages, including clinical trials.
As a development-stage pharmaceutical company, Enveric Biosciences does not currently have commercialized products available for sale. Therefore, it does not have major customers, either other companies or individual consumers, purchasing its products in the traditional sense. Its focus is on advancing its drug candidates through clinical development and regulatory processes.
AI Analysis | Feedback
null
AI Analysis | Feedback
Joseph Tucker, Ph.D. Chief Executive Officer, Director
Joseph Tucker has been the Chief Executive Officer and a Director of Enveric Biosciences since September 16, 2021. He holds a Ph.D. in Biochemistry & Molecular Biology from the University of Calgary. Dr. Tucker has executive experience with both privately held and publicly listed biotechnology companies, having served as CEO, CFO, and Vice President for five biotech companies over 15 years. Prior to Enveric, he led MagicMed Industries Inc. as CEO, President, and Director, a company that was subsequently acquired by Enveric Biosciences. His past roles also include Executive Chairman of Willow Biosciences Inc. and CEO, President, and Director of Epimeron Inc. He has also operated and financed early-stage biotech ventures such as VirTech Bio, Taiga Bioactives, SolAeroMed, and Pharmavation. Earlier in his career, he worked as a healthcare stock market analyst for two investment banks and in technology commercialization for a university technology transfer office.
Kevin Coveney, CPA Chief Financial Officer
Kevin Coveney was appointed Chief Financial Officer of Enveric Biosciences, effective March 13, 2023, bringing over 30 years of experience in accounting, finance, and operations. He has previously served as CFO for multiple biotechnology companies, including Memgen, Inc., a clinical-stage immune-oncology company, and Q-State Biosciences, a biotech company focused on CNS disorders. Before Q-State, Mr. Coveney was Senior Vice President of Finance, HR & IT at Vedanta Biosciences, a private microbiome company. He has also served as a fractional CFO for emerging life science and digital health companies.
Peter Facchini, Ph.D. Chief Innovation Officer
Peter Facchini has served as the Chief Innovation Officer of Enveric Biosciences. He is a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary, where he held the Canada Research Chair in Plant Metabolic Processes Biotechnology. Dr. Facchini co-founded and served as Chief Scientific Officer of Willow Biosciences Inc. and Epimeron Inc. He has published over 160 scientific papers and co-invented more than 30 patents, and is recognized as an international leader in the biochemistry and biotechnology of natural product metabolism.
Jillian Hagel Vice President, Innovation
Jillian Hagel is the Vice President, Innovation at Enveric Biosciences.
Joseph Tucker has been the Chief Executive Officer and a Director of Enveric Biosciences since September 16, 2021. He holds a Ph.D. in Biochemistry & Molecular Biology from the University of Calgary. Dr. Tucker has executive experience with both privately held and publicly listed biotechnology companies, having served as CEO, CFO, and Vice President for five biotech companies over 15 years. Prior to Enveric, he led MagicMed Industries Inc. as CEO, President, and Director, a company that was subsequently acquired by Enveric Biosciences. His past roles also include Executive Chairman of Willow Biosciences Inc. and CEO, President, and Director of Epimeron Inc. He has also operated and financed early-stage biotech ventures such as VirTech Bio, Taiga Bioactives, SolAeroMed, and Pharmavation. Earlier in his career, he worked as a healthcare stock market analyst for two investment banks and in technology commercialization for a university technology transfer office.
Kevin Coveney, CPA Chief Financial Officer
Kevin Coveney was appointed Chief Financial Officer of Enveric Biosciences, effective March 13, 2023, bringing over 30 years of experience in accounting, finance, and operations. He has previously served as CFO for multiple biotechnology companies, including Memgen, Inc., a clinical-stage immune-oncology company, and Q-State Biosciences, a biotech company focused on CNS disorders. Before Q-State, Mr. Coveney was Senior Vice President of Finance, HR & IT at Vedanta Biosciences, a private microbiome company. He has also served as a fractional CFO for emerging life science and digital health companies.
Peter Facchini, Ph.D. Chief Innovation Officer
Peter Facchini has served as the Chief Innovation Officer of Enveric Biosciences. He is a Professor of Plant Biochemistry in the Department of Biological Sciences at the University of Calgary, where he held the Canada Research Chair in Plant Metabolic Processes Biotechnology. Dr. Facchini co-founded and served as Chief Scientific Officer of Willow Biosciences Inc. and Epimeron Inc. He has published over 160 scientific papers and co-invented more than 30 patents, and is recognized as an international leader in the biochemistry and biotechnology of natural product metabolism.
Jillian Hagel Vice President, Innovation
Jillian Hagel is the Vice President, Innovation at Enveric Biosciences.
AI Analysis | Feedback
Here are the key risks to Enveric Biosciences (ENVB):
- Financial Challenges and Going Concern Risk: Enveric Biosciences faces significant financial hurdles, including a lack of revenue growth and ongoing substantial losses. The company is actively burning through cash to fund its research and development efforts. Management and independent accounting firms have expressed significant doubt about Enveric's ability to continue as a going concern without securing additional funding, which is not guaranteed and may not be on favorable terms.
- Drug Development and Regulatory Risks: As a biotechnology company, Enveric Biosciences operates in a high-risk environment where the success of its product pipeline is uncertain. There is no guarantee that promising preclinical data will translate into successful human clinical trials, or that its product candidates, such as EB-003, will prove efficacious or safe. The company also faces inherent risks related to regulatory approvals, including potential delays in planned clinical trials and the challenges of obtaining necessary governmental approvals to market its products.
- Intense Competition and Intellectual Property Challenges: The pharmaceutical industry, particularly in the development of treatments for psychiatric and neurological disorders, is highly competitive. Enveric Biosciences competes with numerous companies, some with significantly greater financial and technical resources. While the company is focused on securing and defending its intellectual property, including an expanding patent estate, it must constantly navigate a competitive landscape and potential legal challenges to its patents.
AI Analysis | Feedback
null
AI Analysis | Feedback
Enveric Biosciences (symbol: ENVB) is developing various cannabinoid medicines for cancer care and other indications. The addressable markets for its main products are substantial, with global market sizes detailed below.
- EV104 for the treatment of osteoarthritis: The global osteoarthritis therapeutics market size was estimated at USD 5.49 billion in 2025 and is projected to reach USD 10.89 billion by 2033. Another estimate places the global osteoarthritis treatment market at USD 9.8 billion in 2025, projected to reach USD 15.3 billion by 2032. The North American region holds the largest share of this market.
- EVM-101 and EVM-201 for the treatment of cancer related distress: This addresses needs within supportive cancer care and the broader mental health market. The global cancer care supportive products market size is valued at US$ 19.4 billion in 2025 and is projected to reach US$ 24.7 billion by 2032. North America currently dominates this market. Additionally, the global mental health market size is expected to be worth around USD 490.91 billion in 2025, growing to approximately USD 682.51 billion by 2035.
- EVM-301 for the treatment of mental health indication: The global mental health market size is estimated at USD 490.91 billion in 2025, with projections to reach USD 682.51 billion by 2035. Another source values the mental health market at USD 95.03 billion in 2025, with an estimated growth to USD 115.63 billion by 2031. North America holds a significant share in this market.
- EV102, a cannabinoid cream for topical skin application: This product falls under the broader medical cannabis and cannabidiol (CBD) topical markets. The global medical cannabis market was valued at USD 25.86 billion in 2024 and is expected to reach USD 133.73 billion by 2032. Topicals are a specific route of administration within this market. Furthermore, the global cannabidiol market size is calculated at USD 10.39 billion in 2025 and is projected to reach around USD 45.17 billion by 2035, with topicals being a product type contributing to this growth.
- EV101, a cannabinoid and chemotherapy combination therapy: This product targets the substantial oncology and chemotherapy markets. The global chemotherapy market size is estimated to be valued at USD 10.29 billion in 2025 and is projected to reach around USD 21.33 billion by 2035. The global cancer/oncology drugs market size was calculated at USD 192.39 billion in 2025 and is predicted to increase to approximately USD 554.69 billion by 2035. The overall global oncology market size was USD 321.19 billion in 2024 and is expected to reach around USD 903.81 billion by 2034.
AI Analysis | Feedback
Enveric Biosciences (ENVB) is focused on several key drivers for future revenue growth over the next 2-3 years, primarily through the advancement of its drug pipeline and strategic out-licensing agreements.
Here are 3-5 expected drivers of future revenue growth:
- Advancement and Potential Commercialization of Lead Candidate EB-003: Enveric Biosciences' lead drug candidate, EB-003, a neuroplastogenic therapeutic for neuropsychiatric indications, is a significant focus for future growth. The company is progressing towards filing an Investigational New Drug (IND) application and initiating its first-in-human clinical study in 2026. Positive preclinical data, including its potential in treating mental health disorders, supports its development. While direct product sales are a longer-term prospect, successful progression through clinical trials could trigger substantial milestone payments from potential partners or eventual market entry.
- Milestone Payments and Royalties from Out-licensing Agreements: Enveric has actively pursued and secured various out-licensing deals for its compounds, which are expected to generate non-dilutive revenue through milestone payments and future royalties. For instance, in Q1 2024, the company announced seven non-binding term sheets with four strategic partners, potentially totaling up to approximately $410 million in milestone payments, plus future royalties. More specific agreements include a patented topical product out-licensed for up to $61 million in milestone payments and tiered royalties, and the EVM201 program (including EB-002) out-licensed for potentially up to $62 million in milestones and single-digit royalties.
- Expansion and Monetization of the Intellectual Property (IP) Portfolio: The company emphasizes its intellectual property as a core value proposition, continuously expanding its patent estate to build a competitive advantage around its lead assets and future pipeline. A recent example includes a new patent granted in February 2025 for its EVM401 Series of mescaline-derived compounds, broadening potential treatments for addiction and mental health. A robust IP portfolio enhances the value of their assets for future out-licensing opportunities and collaborations with larger pharmaceutical companies, contributing to revenue through licensing fees and partnerships.
- Growth of Recently Out-licensed Products in New Markets: Beyond initial milestone payments, the out-licensing agreements include tiered royalties on future sales of the developed products. As these out-licensed compounds, such as the topical product for radiation dermatitis or cannabinoid-COX-2 conjugate compounds for joint diseases, advance through development by their partners and potentially reach the market, the associated royalties will contribute to Enveric's recurring revenue stream.
AI Analysis | Feedback
Share Issuance
- In February 2026, Enveric Biosciences launched a $1,346,000 at-the-market (ATM) stock program.
- The company executed a registered direct offering in January 2026, issuing 328,802 shares at $4.41 per share, which generated gross proceeds of approximately $1.45 million and estimated net proceeds of about $1.25 million.
- Cash provided by financing activities, primarily from warrant exercises and common stock sales, amounted to $7,210,386 for the nine months ended September 30, 2024.
Inbound Investments
- Lind Global Fund III LP disclosed a 9.99% beneficial ownership in Enveric Biosciences in January 2026, which included common shares and warrants.
- For the six months ended June 30, 2025, Enveric Biosciences raised net proceeds of $4.9 million through various financing tools to fund its operations.
Capital Expenditures
- Enveric Biosciences Inc. reported capital expenditures of -$15 in the fourth quarter of 2023.
- As of its latest balance sheet, the company's physical assets amounted to approximately $196.5k.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Enveric Biosciences Earnings Notes | 12/16/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 4.14 |
| Mkt Cap | 0.6 |
| Rev LTM | 2 |
| Op Inc LTM | -60 |
| FCF LTM | -43 |
| FCF 3Y Avg | -49 |
| CFO LTM | -43 |
| CFO 3Y Avg | -49 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 75.6% |
| Rev Chg 3Y Avg | 145.4% |
| Rev Chg Q | 9.4% |
| QoQ Delta Rev Chg LTM | 10.9% |
| Op Inc Chg LTM | 12.0% |
| Op Inc Chg 3Y Avg | 21.3% |
| Op Mgn LTM | -746.9% |
| Op Mgn 3Y Avg | -8,341.1% |
| QoQ Delta Op Mgn LTM | 1.6% |
| CFO/Rev LTM | -651.0% |
| CFO/Rev 3Y Avg | -6,369.5% |
| FCF/Rev LTM | -651.0% |
| FCF/Rev 3Y Avg | -6,453.4% |
Segment Financials
Revenue by Segment| $ Mil | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|
| Developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression | 40 | 43 | 49 | 36 |
| Total | 40 | 43 | 49 | 36 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Developing novel neuroplastogenic small-molecule therapeutics for the treatment of depression | 5 | 3 | 4 | 20 | 27 |
| Total | 5 | 3 | 4 | 20 | 27 |
Price Behavior
Price Behavior
| Market Price | $1.37 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 02/23/2007 | |
| Distance from 52W High | -92.1% | |
| 50 Days | 200 Days | |
| DMA Price | $2.61 | $4.67 |
| DMA Trend | down | up |
| Distance from DMA | -47.6% | -70.7% |
| 3M | 1YR | |
| Volatility | 236.6% | 175.1% |
| Downside Capture | 83.62 | 428.11 |
| Upside Capture | -78.45 | 33.02 |
| Correlation (SPY) | 1.4% | 10.5% |
ENVB Betas & Captures as of 5/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 1.09 | -3.13 | 0.15 | 0.84 | 1.55 | 1.04 |
| Up Beta | -5.21 | -3.20 | -0.11 | 0.22 | -0.85 | 0.63 |
| Down Beta | -3.93 | 8.80 | 3.98 | 0.48 | 2.01 | 0.74 |
| Up Capture | -168% | -59% | -13% | -11% | 61% | 1% |
| Bmk +ve Days | 13 | 28 | 36 | 67 | 141 | 432 |
| Stock +ve Days | 6 | 18 | 26 | 52 | 107 | 288 |
| Down Capture | 1178% | -799% | -12% | 209% | 206% | 114% |
| Bmk -ve Days | 7 | 13 | 27 | 57 | 109 | 318 |
| Stock -ve Days | 14 | 23 | 37 | 71 | 135 | 442 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENVB | |
|---|---|---|---|---|
| ENVB | -90.7% | 174.8% | -0.63 | - |
| Sector ETF (XLV) | 14.4% | 15.0% | 0.69 | -0.9% |
| Equity (SPY) | 27.2% | 12.4% | 1.66 | 10.9% |
| Gold (GLD) | 25.8% | 27.4% | 0.82 | 3.5% |
| Commodities (DBC) | 23.3% | 18.9% | 0.98 | 9.8% |
| Real Estate (VNQ) | 13.6% | 13.5% | 0.69 | 5.2% |
| Bitcoin (BTCUSD) | -37.7% | 42.4% | -1.00 | 3.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENVB | |
|---|---|---|---|---|
| ENVB | -85.6% | 155.7% | -0.62 | - |
| Sector ETF (XLV) | 6.1% | 14.7% | 0.23 | 7.0% |
| Equity (SPY) | 13.8% | 17.1% | 0.63 | 15.8% |
| Gold (GLD) | 17.6% | 18.2% | 0.78 | 3.0% |
| Commodities (DBC) | 7.8% | 19.4% | 0.30 | 3.5% |
| Real Estate (VNQ) | 2.5% | 18.8% | 0.04 | 10.5% |
| Bitcoin (BTCUSD) | 12.1% | 54.2% | 0.42 | 2.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with ENVB | |
|---|---|---|---|---|
| ENVB | -78.9% | 161.9% | -0.45 | - |
| Sector ETF (XLV) | 9.7% | 16.6% | 0.47 | 9.5% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 14.8% |
| Gold (GLD) | 12.8% | 16.1% | 0.66 | 1.8% |
| Commodities (DBC) | 6.2% | 18.0% | 0.27 | 5.8% |
| Real Estate (VNQ) | 5.6% | 20.7% | 0.23 | 8.0% |
| Bitcoin (BTCUSD) | 60.7% | 66.8% | 1.00 | 6.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 6/17/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/15/2026 | -1.7% | -3.1% | -35.4% |
| 3/27/2026 | -4.8% | 5.9% | 183.0% |
| 11/14/2025 | -5.9% | 13.1% | 4.7% |
| 8/14/2025 | 0.0% | 4.5% | -12.6% |
| 5/14/2025 | -3.8% | -5.7% | -7.6% |
| 11/14/2024 | -8.1% | -15.1% | -9.3% |
| 8/12/2024 | 1.4% | -3.9% | -5.4% |
| 5/15/2024 | -4.0% | 0.9% | -8.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 5 | 3 |
| # Negative | 8 | 10 | 12 |
| Median Positive | 1.4% | 5.9% | 9.5% |
| Median Negative | -3.9% | -5.9% | -11.8% |
| Max Positive | 11.9% | 13.1% | 183.0% |
| Max Negative | -8.1% | -21.0% | -35.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/15/2026 | -1.7% | -3.1% | -35.4% |
| 3/27/2026 | -4.8% | 5.9% | 183.0% |
| 11/14/2025 | -5.9% | 13.1% | 4.7% |
| 8/14/2025 | 0.0% | 4.5% | -12.6% |
| 5/14/2025 | -3.8% | -5.7% | -7.6% |
| 11/14/2024 | -8.1% | -15.1% | -9.3% |
| 8/12/2024 | 1.4% | -3.9% | -5.4% |
| 5/15/2024 | -4.0% | 0.9% | -8.6% |
| 3/26/2024 | 1.0% | 8.6% | -11.0% |
| 11/13/2023 | -1.3% | -3.9% | -7.9% |
| 8/14/2023 | -1.5% | -21.0% | -12.5% |
| 4/3/2023 | 1.4% | -16.8% | 9.5% |
| 4/1/2022 | 1.3% | -7.2% | -16.8% |
| 5/20/2021 | 11.9% | -6.2% | -14.8% |
| 4/1/2021 | 2.0% | -4.9% | -22.5% |
| SUMMARY STATS | |||
| # Positive | 7 | 5 | 3 |
| # Negative | 8 | 10 | 12 |
| Median Positive | 1.4% | 5.9% | 9.5% |
| Median Negative | -3.9% | -5.9% | -11.8% |
| Max Positive | 11.9% | 13.1% | 183.0% |
| Max Negative | -8.1% | -21.0% | -35.4% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/27/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/26/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 03/31/2026 | 05/15/2026 | 10-Q |
| 12/31/2025 | 03/27/2026 | 10-K |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 08/14/2025 | 10-Q |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 03/28/2025 | 10-K |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 08/12/2024 | 10-Q |
| 03/31/2024 | 05/15/2024 | 10-Q |
| 12/31/2023 | 03/26/2024 | 10-K |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 08/11/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/31/2023 | 10-K |
| 09/30/2022 | 11/14/2022 | 10-Q |
| 06/30/2022 | 08/12/2022 | 10-Q |
| 03/31/2022 | 05/13/2022 | 10-Q |
| 12/31/2021 | 03/31/2022 | 10-K |
| 09/30/2021 | 11/15/2021 | 10-Q |
| 06/30/2021 | 08/13/2021 | 10-Q |
| 03/31/2021 | 05/17/2021 | 10-Q |
| 12/31/2020 | 04/01/2021 | 10-K |
| 09/30/2020 | 11/16/2020 | 10-Q |
| 06/30/2020 | 08/14/2020 | 10-Q |
| 03/31/2020 | 05/15/2020 | 10-Q |
| 12/31/2019 | 03/25/2020 | 10-K |
| 09/30/2019 | 11/08/2019 | 10-Q |
| 06/30/2019 | 08/14/2019 | 10-Q |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 6/16/2026